Stanford researchers have developed ModulADAR - a novel RNA sensing platform that enables precise, cell-type or state-specific activation of mRNA expression using ADAR editing, offering unparalleled flexibility and specificity for targeted RNA therapeutics.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Stanford researchers have developed an LVCTM3 system for producing lentiviral vectors and other viral particles, offering a cost-effective, simplified and scalable solution for various applications from gene therapy to vaccine development.
Stanford researchers have discovered that tumors increase the risk of atherosclerosis by regulating expression of a specific gene that stimulates angiogenesis and intraplaque neovessel formation.
Stanford researchers have developed a method to overcome the packaging capacity limitation of adeno-associated virus (AAV) Vector CRISPR/Cas9 systems to help treat genetic diseases for which the cargo is larger than 4.7kb.
Stanford researchers have developed AZD7648, a novel DNA-PK inhibitor that enhances HDR efficiency in CRISPR-Cas9 gene editing by shifting DNA repair from the error-prone NHEJ pathway to the precise HDR pathway, significantly improving gene targeting outcomes in human cells fo
Stanford researchers have discovered using a novel assay that a large proportion of CRISPR/AAV modified cells contain hidden concatemeric knockins that affect gene expression, and therefore developed a strategy to reduce their occurrence.
Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.
Researchers at Stanford University have developed a novel platform for genetically engineering cells within a living organism, circumventing previous limitations related to accessing target tissues and the size of the genetic payload.
Stanford researchers have developed a new gene editing approach that enables red blood cell-specific gene expression for the treatment of enzyme deficiencies.
Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
The cost of DNA and RNA sequencing have decreased in recent years to aid effective research and clinical applications; however, the labor time and throughput of preparing DNA and RNA sequencing libraries remains a challenge.